Billionaire Israel "Izzy" Englander Has Loaded Up on This Dividend King. Should You?

Group 1 - Billionaire Israel "Izzy" Englander significantly increased his stake in AbbVie by 416% in Q2 2025, highlighting the stock's appeal as a Dividend King with a history of 53 consecutive years of dividend increases [2][3][8] - AbbVie has successfully managed the loss of exclusivity for its top-selling drug Humira, with successors Skyrizi and Rinvoq projected to generate over $25 billion in sales this year [5][10] - The stock is considered attractively valued and offers a solid dividend yield, making it an appealing investment choice for hedge funds like Millennium Management [8][9] Group 2 - Englander's investment strategy included a notable purchase of 2.3 million shares of Applovin, increasing his position by more than 9 times, indicating a diverse investment approach [4] - AbbVie remains a significant holding within Millennium Management's extensive portfolio of over 3,900 stocks, reflecting its importance in the healthcare sector [6]